eligibility_summary
Adults ≥18 with biopsy-proven marginal zone lymphoma (splenic, nodal, or extranodal MALT), ≥1 measurable lesion, needing systemic therapy (GELF or symptoms/organ dysfunction), and not suitable for local RT or progressed after RT (incl. Ann Arbor noncontig II/III–IV non-gastric MALT or nodal MZL, SMZL, gastric MALT Lugano II2/IIE/IV). ECOG 0–2, life ≥3 mo, consent. Exclude: other cancers, CNS lymphoma, drug allergy, active infection/uncontrolled HBV, HIV/AIDS, pregnancy/lactation/no contraception, or other serious issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06454968 evaluates first-line OGL in marginal zone lymphoma. Interventions and mechanisms: • Orelabrutinib: oral small-molecule Bruton’s tyrosine kinase (BTK) inhibitor, blocks B‑cell receptor (BCR) signaling and downstream NF‑κB survival pathways in malignant B cells. • Obinutuzumab: IV, type II glycoengineered anti‑CD20 monoclonal antibody, induces direct B‑cell death and enhanced antibody‑dependent cellular cytotoxicity (ADCC). • Lenalidomide: oral immunomodulatory drug (IMiD), cereblon E3‑ligase modulator causing IKZF1/3 degradation, augments T/NK‑cell cytotoxicity, modulates cytokines, and is anti‑angiogenic. Targets/pathways: CD20+ marginal‑zone B cells, BTK/BCR‑NF‑κB axis, CD20 antigen, immune effector cells (NK, T, macrophages via FcγR) and the tumor microenvironment. Primary endpoint: best complete response rate.